Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1. 系统已在2025-09-19 17:20:29对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
G Mountzios, L Sun, BC Cho, U Demirci…
… England Journal of …, 2025
Mass Medical Soc
Background Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known. Methods We conducted a multinational, phase 3, open-label trial to compare tarlatamab with chemotherapy as second-line treatment in …
